Democratic report: Trump held up to $39.1m in drug stocks before Medicare provision
Democrats on Congress's Joint Economic Committee say Trump's portfolio held up to $39.1m in drugmakers that benefited from a 2025 law's Medicare negotiation exemptions. The White House says the portfolio is independently managed and rejects the conflict-of-interest charge.
1 / 2
The story, neutrally told
Mixed · 2Democrats on Congress's Joint Economic Committee (JEC) released a report on Friday 16 October 2026 saying President Donald Trump's investment portfolio held up to $39.1 million in pharmaceutical companies that benefited from a provision of the 2025 Republican tax and spending law. NewsweekN “Up to $39.1 million was held in companies that benefited from a provision of Republicans' 2025 tax and spending law” Read at Newsweek ↗ Raw StoryL “An analysis released Friday by Democrats on the congressional Joint Economic Committee” Read at Raw Story ↗ Centre · 1The report puts the maximum reported value of Trump's pharmaceutical holdings at $1.7 million in 2024 and $56.2 million by the end of 2025; the figures are based on ranges in his financial disclosures. NewsweekN “increased from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million by the end of 2025”“Those findings are based on the ranges in Trump's financial disclosures.” Read at Newsweek ↗ Centre · 1According to Newsweek's account of the report, the portfolio bought as much as $2.55 million in shares of benefiting drugmakers on three dates before Trump signed the law in July 2025, including up to $950,000 on 1 July, the day the Senate passed it, and up to $1 million of AbbVie stock in August 2025. NewsweekN “His portfolio purchased as much as $2.55 million in shares of benefiting pharmaceutical companies on three dates before Trump signed the legislation in July 2025.”“After the measure became law, Trump's portfolio bought up to $1 million of AbbVie stock in August 2025 as well.” Read at Newsweek ↗
Mixed · 2The provision expanded an exemption from Medicare's drug price negotiation, created under the 2022 Inflation Reduction Act, for drugs treating rare diseases; it now covers drugs with multiple rare-disease designations and changes when some drugs become eligible for negotiation. NewsweekN “Republicans' 2025 law widened the exclusion to include drugs with multiple rare-disease designations and altered when some drugs become eligible for negotiations.” Read at Newsweek ↗ Raw StoryL “Tucked in the Trump-GOP budget law was a provision exempting some widely used, high-priced prescription drugs from Medicare price negotiations.” Read at Raw Story ↗ Centre · 1The report names drugs including Keytruda, Opdivo, Darzalex, Ultomiris and Adcetris, and says the change could mean $21,800 more in out-of-pocket costs for some autoimmune treatments and $9,000 more for some cancer treatments. NewsweekN “specifically points to drugs including Keytruda, Opdivo, Darzalex, Ultomiris and Adcetris.”“$21,800 more in out-of-pocket costs for treatment of certain autoimmune conditions and $9,000 more for treatment of certain cancers” Read at Newsweek ↗ Left · 1Raw Story, carrying Common Dreams, says Merck's cancer drug Keytruda was temporarily shielded, that Merck appears more than 60 times in Trump's 2025 disclosure, and that Keytruda brought in $18.8 billion in US revenue in 2025; it adds that Trump also bought Johnson & Johnson, AbbVie, Pfizer and Amgen stock, each with at least one drug that benefited. Raw StoryL “Merck appears more than 60 times in the president’s 2025 financial disclosure.”“The president also made big purchases of stock in Johnson & Johnson, AbbVie, Pfizer, and Amgen last year.” Read at Raw Story ↗
Left · 1Sen. Maggie Hassan (D-NH), the JEC's ranking member, said Trump and Republicans "intentionally force seniors to pay more for cancer treatment" so drugmakers profit and Trump can personally profit. Raw StoryL “Trump and congressional Republicans intentionally force seniors to pay more for cancer treatment so that Big Pharma can rake in more money that Trump can personally profit from” Read at Raw Story ↗ Centre · 1The White House has denied an ethics problem, accusing Democrats of "attempts to fabricate conflicts of interest" and saying third-party financial institutions manage the portfolio without input from Trump or his family. NewsweekN “It has accused Democrats of "attempts to fabricate conflicts of interest,"”“Trump's investment portfolio is independently managed by third-party financial institutions without input from the president or his family.” Read at Newsweek ↗ Centre · 1Newsweek notes that the timing of the purchases alone does not establish that Trump directed them because of the legislation or traded on nonpublic information, and says a Congressional Budget Office estimate projected the expanded exemptions would raise Medicare costs by about $8.8 billion over 10 years. NewsweekN “The timing of Trump's investments alone does not establish that Trump directed the purchases because of the legislation or traded on nonpublic information.”“increase Medicare costs by about $8.8 billion over 10 years” Read at Newsweek ↗
Centre · 1Supporters of the exemption argued it protects incentives to research rare-disease treatments, while Democrats say it shields highly profitable medicines from negotiation. NewsweekN “The policy was intended to protect incentives for developing treatments for rare diseases”“the broader exemption can protect highly profitable medicines from Medicare negotiations” Read at Newsweek ↗
Every sentence links to the reporting it rests on. The pill in front of each says where its sources sit: Left, Centre or Right when one side supplies at least half of them, Mixed when they are evenly split. The number is how many outlets it cites.
Left1 outlet
- Framing
- Advocacy-style account led by Hassan's accusation that seniors pay more for cancer treatment so Trump can profit.
- Emphasis
- Keytruda/Merck, Big Pharma profits, Trump's drug-pricing deals and Public Citizen's criticism.
- Leaves out or plays down
- Does not include the White House response, the independent-management defence or the caveat that timing does not prove intent.
- Charged language
- “Outrageous”“Big Pharma”“loaded up”
- For example
-
“Trump and congressional Republicans intentionally force seniors to pay more for cancer treatment so that Big Pharma can rake in more money that Trump can personally profit from” — Raw Story
Centre1 outlet
- Framing
- Reports the Democratic report's figures, with the White House denial and caveats on what the timing shows.
- Emphasis
- Purchase dates and amounts, the policy background, the CBO cost estimate, outside commentators and the midterms.
- Leaves out or plays down
- Gives less on specific company revenues and Trump's drug-pricing agreements.
- Charged language
- “giveaway to Big Pharma”
- For example
-
“The timing of Trump's investments alone does not establish that Trump directed the purchases because of the legislation or traded on nonpublic information.” — Newsweek
Right0 outlets
No right outlet in our sources has covered this story yet.
What every side reports
- JEC Democrats released the analysis on Friday.
- Trump's pharmaceutical holdings were put at up to $1.7m in 2024 and up to $56.2m in 2025.
- Up to $39.1m was in companies that benefited from a Medicare negotiation exemption in the 2025 law.
Where accounts differ
-
Whether Trump's holdings amount to a conflict of interest
- Left
- Raw Story relays Hassan's charge that Trump is forcing seniors to pay more so he can personally profit.
- Centre
- Newsweek reports the White House denial and notes timing alone does not show Trump directed purchases or used nonpublic information.
Joint Economic Committee organisation
JEC Democrats say Trump's pharma holdings grew sharply while Republicans passed a giveaway to drugmakers that raises costs for patients.
“Big Pharma raked in higher profits that directly benefitted Trump given how much pharmaceutical stocks he has purchased since returning to office.” — Newsweek
Donald Trump person
The White House, speaking for Trump, denies a conflict of interest and says his portfolio is independently managed by third parties.
“The administration's position is that Trump's portfolio is independently managed by third-party financial institutions” — Newsweek
Left1 article
-
'Outrageous': Trump accused of making seniors 'pay more for cancer treatment' for profit
Critical Presents the JEC analysis and Hassan's accusation as showing Trump profiting at seniors' expense.
Centre1 article
-
Trump Bought Millions in Drug Stocks Before Medicare Change—Democrat Report
Neutral Reports the report's findings alongside the White House denial, caveats and commentator views.
Right0 articles
No coverage yet.
- 16 Oct 23:03 First NewsweekN Trump Bought Millions in Drug Stocks Before Medicare Change—Democrat Report
- 17 Oct 12:09 +13h 6m Raw StoryL 'Outrageous': Trump accused of making seniors 'pay more for cancer treatment' for profit
Times are when each article was published, or when we first saw it if the outlet gave no time.
Ask about this story
Loading…